Maria Cláudia Santos-Silva Selected Research

Chalcones

11/2021	Synthesis of chalcones derived from 1-naphthylacetophenone and evaluation of their cytotoxic and apoptotic effects in acute leukemia cell lines.
9/2017	Cytotoxic effect of a novel naphthylchalcone against multiple cancer cells focusing on hematologic malignancies.
5/2013	Cytotoxic 3,4,5-trimethoxychalcones as mitotic arresters and cell migration inhibitors.
4/2013	Apoptotic events induced by synthetic naphthylchalcones in human acute leukemia cell lines.
9/2010	Induction of apoptosis and cell cycle arrest in L-1210 murine lymphoblastic leukaemia cells by (2E)-3-(2-naphthyl)-1-(3'-methoxy-4'-hydroxy-phenyl)-2-propen-1-one.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Maria Cláudia Santos-Silva Research Topics

Disease

10	Leukemia 11/2021 - 02/2006
8	Neoplasms (Cancer) 02/2022 - 09/2010
5	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2021 - 02/2006
2	Breast Neoplasms (Breast Cancer) 02/2022 - 05/2013
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2021 - 04/2013
2	Melanoma (Melanoma, Malignant) 12/2013 - 11/2011
1	COVID-19 01/2022
1	Critical Illness (Critically Ill) 01/2022
1	Hemolysis 11/2021
1	Lymphoma (Lymphomas) 03/2021
1	Weight Loss (Weight Reduction) 09/2015
1	Mouth Neoplasms (Oral Cancer) 01/2015
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 05/2013
1	Wounds and Injuries (Trauma) 05/2013
1	Hematologic Neoplasms (Hematological Malignancy) 01/2013
1	Necrosis 11/2011

Drug/Important Bio-Agent (IBA)

5	ChalconesIBA 11/2021 - 09/2010
3	Chalcone (Benzalacetophenone)IBA 09/2017 - 04/2013
3	Biological ProductsIBA 12/2013 - 09/2010
2	ImidesIBA 12/2013 - 11/2011
1	Ki-67 Antigen (Ki 67 Antigen)IBA 02/2022
1	Nuclear Proteins (Protein, Nuclear)IBA 02/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Interleukin-10 (Interleukin 10)IBA 01/2022
1	Interleukin-17 (Interleukin 17)IBA 01/2022
1	HLA-DR Antigens (HLA-DR)IBA 01/2022
1	Interleukin-6 (Interleukin 6)IBA 01/2022
1	InterleukinsIBA 01/2022
1	Interleukin-8 (Interleukin 8)IBA 01/2022
1	lupeolIBA 11/2021
1	ThiosemicarbazonesIBA 03/2021
1	2,4-dinitrobenzenesulfonamideIBA 01/2021
1	PlastoquinoneIBA 01/2020
1	miconidinIBA 10/2019
1	Acetates (Acetic Acid Esters)FDA Link 10/2019
1	compound 21IBA 05/2017
1	CurcuminIBA 01/2015
1	ChitosanIBA 01/2015
1	NaphthalimidesIBA 12/2013
1	MaleimidesIBA 12/2013
1	Colchicine FDA LinkGeneric 05/2013
1	TubulinIBA 05/2013
1	LigandsIBA 05/2013
1	2-naphthaldehydeIBA 04/2013
1	1-naphthaldehydeIBA 04/2013
1	Subfamily B ATP Binding Cassette TransporterIBA 01/2013
1	Proteins (Proteins, Gene)FDA Link 01/2013
1	BromidesIBA 11/2011
1	FITC-annexin A5IBA 11/2011
1	Acridine OrangeIBA 11/2011
1	Glutathione (Reduced Glutathione)IBA 02/2006
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 02/2006
1	Paclitaxel (Taxol)FDA LinkGeneric 02/2006
1	NF-kappa B (NF-kB)IBA 02/2006

Therapy/Procedure

4	Therapeutics 01/2021 - 09/2010
1	Intravenous Administration 11/2021
1	Aftercare (After-Treatment) 09/2015